Aim Pharmakon (India) Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
- Revenue Growth %
- Profit Growth 79.89%
- Net Worth -0.23%
- Total Assets -0.57%
About Aim Pharmakon (India)
Aim Pharmakon (India) Private Limited (APIPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 June 2005 and has a history of 19 years and seven months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Suresh Narasinha and Raju Puntambekar serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397MH2005PTC154275
-
Company No.
154275
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Jun 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Aim Pharmakon (India)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raju Puntambekar
|
Director | 28-Jun-2005 | Current |
|
Suresh Narasinha
|
Director | 28-Jun-2005 | Current |
Financial Performance of Aim Pharmakon (India).
Aim Pharmakon (India) Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 79.89% increase in profit. The company's net worth dipped by a decrease of 0.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aim Pharmakon (India)?
In 2019, Aim Pharmakon (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Reshmina Clothing LlpSuresh Narasinha is a mutual person
Charges (Loans)
₹5.00 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Maharashtra : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jul 2007 | Bank Of Maharashtra | ₹2.50 M | Open |
| 26 Jun 2007 | Bank Of Maharashtra | ₹2.50 M | Open |
How Many Employees Work at Aim Pharmakon (India)?
Unlock and access historical data on people associated with Aim Pharmakon (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aim Pharmakon (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aim Pharmakon (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.